Absci Corporation has begun dosing patients in the first human trial of ABS-201, a monoclonal antibody designed entirely by generative AI. The Phase 1/2a trial, dubbed HEADLINE, commenced on December 4, 2025, in Australia, potentially setting a record for swift development in biotech history: approximately 24 months.
ABS-201 targets the prolactin receptor (PRLR) to enhance hair follicle regeneration, serving as a treatment for androgenetic alopecia, the leading cause of hair loss. With an engineered extended half-life, it remains active in the body longer than standard antibodies, showing superior hair regrowth in preclinical data compared to existing treatments. The HEADLINE trial involves up to 227 healthy participants, randomized, double-blind, and placebo-controlled.
A multi-ascending dose phase is expected in Q2 2026, with proof-of-concept data anticipated in the second half of 2026.
Absci's Integrated Drug Creation platform aims to shorten the traditional drug discovery process. ABS-201 represents its first clinical test. In January 2025, Absci partnered with AMD, securing a $20 million investment to enhance its AI capabilities. In mid-2025, the company raised $64 million in equity financing, extending its operational capacity into mid-2028.
Absci trades on NASDAQ under the ticker ABSI. Phase 1/2a trials are still early-stage, with most drugs not reaching the market. Successful hair regrowth endpoints must demonstrate statistically significant improvement over placebo in controlled environments.